References
- Phanuphak N and Gulick RM. HIV treatment and prevention 2019: current
standards of care. Curr Opin HIV AIDS 2020 Jan;15(1):4-12.
- Gameiro J, Jorge S and Lopes JA. HIV and renal disease: a contemporary
review. Int J STD AIDS 2018 Jun;29(7):714-719.
- European AIDS Clinical Society (EACS) GuidelinesVersion 9.1: European
AIDS Clinical Society (EACS); 2018. http://www.eacsociety.org/
files/2018_guidelines-9.1-english.pdf. Accessed 13 Jan 2019.
- Cid‐Silva P, Fernández‐Bargiela N, Margusino‐Framiñán L, et al.
Treatment with tenofovir alafenamide fumarate worsens the lipid
profile of HIV‐infected patients versus treatment with tenofovir
disoproxil fumarate, each coformulated with elvitegravir, cobicistat,
and emtricitabine. Basic Clin Pharmacol Toxicol. 2019;124(4):479–490.
- Wyatt CM, Klotman PE. Overview of kidney disease in HIV-positive
patients UpToDate,Sep 2020.
- Ryom L, Mocroft A, Kirk O, et al. Association between antiretroviral
exposure and renal impairment among HIV-positive persons with normal
baseline renal function: the D:A:D study. J Infect Dis 2013; 207:
1359–69.
- Mocroft A, Kirk O, Reiss P, et al. Estimated glomerular filtration
rate, chronic kidney disease and antiretroviral drug use in
HIV-positive patients. AIDS 2010; 24: 1667–78.
- Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure
with kidney disease risk in HIV infection. AIDS 2012; 26: 867–75.
- Alfano G, Cappelli G, Fontana F, et al. Kidney Disease in HIV
Infection. J Clin Med. 2019 Aug 19;8(8):1254.
- Lundgren JD, Babiker AG, Gordin F, et al. INSIGHT START Study Group.
Initiation of antiretroviral therapy in early asymptomatic HIV
infection. N Engl J Med 2015; 373:795 – 807.
- Danel C, Moh R, Gabillard D, et al. TEMPRANO ANRS 12136 Study Group. A
trial of early antiretrovirals and isoniazid preventive therapy in
Africa. N Engl J Med 2015; 373:808 – 822.
- Milburn J, Jones R and Levy JB. Renal effects of novel antiretroviral
drugs. Nephrol Dial Transplant (2017) 32: 434–439.
- WHO. Updated recommendations on first-line and second-line
antiretroviral regimens and post-exposure prophylaxis and
recommendations on early infant diagnosis of HIV Interim guidance.
World Health Organization; 2019
https://www.who.int/hiv/pub/guidelines/ ARV2018update/en/.
- Tan Q, He YH, Yang TT, et al. Effects of long-term exposure to
tenofovir disoproxil fumarate-containing antiretroviral therapy on
renal function in HIV-positive Chinese patients. Journal of
Microbiology, Immunology and Infection (2019) 52, 710-719.
- Patel KK, Patel AK, Ranjan RR, et al. Tenofovir-associated renal
dysfunction in clinical practice: an observational cohort from western
India. Indian J Sex Transm Dis. 2010;31:30–4.
- Izzedine H, Isnard-Bagnis C, Hulot J-S, et al. Renal safety of
tenofovir in HIV treatment-experienced patients. AIDS.
2004;18:1074–6.
- Pinto Neto LF, Bassetti BR, Fraga IH, et al. Nephrotoxicity during
tenofovir treatment: a three-year follow-up study in a Brazilian
reference clinic. Braz J Infect Dis. 2016;20(1):14–18.
- Cooper RD, Wiebe N, Smith N, et al. Systematic review and
meta-analysis: renal safety of Tenofovir Diproxil Fumarate in
HIV-infected patients. Clin Infect Dis. 2010;51:496–505.
- Mocroft A, Lundgren JD, Ross M, et al. for the Data Collection on
Adverse events of Anti-HIV Drugs (D:A:D) Study*. Cumulative and
current exposure to potentially nephrotoxic antiretrovirals and
development of chronic kidney disease in HIV-positive individuals with
a normal baseline estimated glomerular filtration rate: a prospective
international cohort study. Lancet HIV 2016; 3(1): e23–32.
- Sax PE, Zolopa A, Brar I, et al. Tenofovir alafenamide vs. tenofovir
disoproxil fumarate in single tablet regimens for initial HIV-1
therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr 2014;
67: 52–58.
- Aloy B, Tazi I, Bagnis CI, et al. Is Tenofovir Alafenamide Safer than
Tenofovir Disoproxil Fumarate for the Kidneys? AIDS Rev. Oct-Dec
2016;18(4):184-192.
- Mayer KH, Molina JM, Thompson MA, et al. Emtricitabine and tenofovir
alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV
pre-exposure prophylaxis (DISCOVER): primary results from a
randomised, double-blind, multicentre, active-controlled, phase 3,
non-inferiority trial. Lancet 2020; 396: 239–54.
- Sax PE, Wohl D, Yin MT, et al. For the GS-US-292-0104/0111 Study
Team*. Tenofovir alafenamide versus tenofovir disoproxil fumarate,
coformulated with elvitegravir, cobicistat, and emtricitabine, for
initial treatment of HIV-1 infection: two randomised, double-blind,
phase 3, non-inferiority trials. Lancet 2015; 385: 2606–15.
- MS, CA, ME. Abacavir/lamivudine/dolutegravir single tablet regimen in
patients with human immunodeficiency virus and end-stage renal disease
on hemodialysis. Int J STD AIDS. 2019 Feb;30(2):181-187.
- Lindeman TA, Duggan JM, Sahloff EG. Evaluation of serum creatinine
changes with integrase inhibitor use in human immunodeficiency virus-1
infected adults. Open Forum Infect Dis. 2016;3(2):ofw053.
- Koteff J, Borland J, Chen S, et al. A Phase 1 study to evaluate the
effect of dolutegravir on renal function via measurement of iohexol
and para-aminohippurate clearance in healthy subjects. Br J Clin
Pharmacol. 2013;75(4):990–6.
- Raffi. F, Rachlis A, Stellbrink HJ, et al. On behalf of the SPRING-2
study group. Once-daily dolutegravir versus raltegravir in
antiretroviral-naive adults with HIV-1 infection: 48 week results from
the randomised, double-blind, non-inferiority SPRING-2 study. Lancet
2013; 381: 735–43.
- Singh
RP,
Shaik
JSB,
Skoura
N, et al. Effects of Low- and High-Mineral Content Water on the
Relative Bioavailability of a Coformulated
Abacavir/Dolutegravir/Lamivudine Dispersible Tablet in Healthy Adults.
J Acquir
Immune Defic Syndr. 2018 Dec 15; 79(5): 631–638.
- Walmsley
S, Baumgarten
A,
Berenguer
J, et al. Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the
Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients:
Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial
J Acquir Immune Defic Syndr. 2015 Dec 15;70(5):515-9.